Generic Name:
Nab-paclitaxel
Project Status:
Complete
Therapeutic Area:
Metastatic Pancreatic Cancer
Manufacturer:
Celgene Inc.
Brand Name:
Abraxane
Project Line:
Reimbursement Review
Project Number:
PC0037-000
NOC Date:
Details
Strength:
100 mg/vial
Tumour Type:
Gastrointestinal
Indications:
Metastatic Pancreatic Cancer
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
pERC Meeting:
Final Recommendation Issued: